Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,710.00
Bid: 1,722.00
Ask: 1,728.00
Change: -60.00 (-3.39%)
Spread: 6.00 (0.348%)
Open: 1,784.00
High: 1,784.00
Low: 1,710.00
Prev. Close: 1,770.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Business Expansion in China

20 Feb 2009 07:00

RNS Number : 6231N
Genus PLC
20 February 2009
 



For immediate release 20 February 2009

Genus plc

("Genus" or "the Company")

Business Expansion in China

Genus, a world leading animal genetics company, is pleased to announce significant advances in its strategy for expansion in China with progress being made in both the bovine and porcine sectors These initiatives represent major steps forward in the Company's strategic focus on growth in emerging markets whilst maintaining its leading status in the developed world.

Joint Venture with Leading Chinese Dairy

Genus has made an important breakthrough in its strategy to enter the local market in China. An agreement in principle has been made with Mengniu, the market leading Chinese dairy company, to establish a joint venture to produce elite bovine genetics in ChinaThe local semen that will be produced will be marketed and sold in China to Mengniu's substantial existing farmer supplier base through already established distribution channels.

Mengniu produces, markets and distributes a wide range of dairy products throughout China, including Hong Kong and Macau, and operates from 23 production bases that have an annual total output of approximately 4.5 million tons of dairy product. Mengniu's contract farmers supply milk from almost twice the number of cows that comprise the UK market.  Mengniu was founded in 1999, is listed on the Hong Kong Stock Exchange and now has a market capitalisation of approximately £1.5bn.

The joint venture will be confirmed by a formal agreement and in anticipation of the formation of the joint venture, Genus is transferring 14 progeny tested bulls from its Australian stud to China as well as a quantity of semen from the USA to represent opening stock.

Increased Porcine Capacity in China

In September 2008 Genus announced the expansion of its porcine breeding stock production network in China. Genus is pleased to announce a further increase in this capacity. Genus has contracted to lease production nucleus capacity in Liaoning province to meet forecast increases in demand as more world class pig units are established as a result of Chinese government initiatives to promote modernisation in the agricultural sector. This investment underpins Genus’ position as a market leader in China for the supply of elite genetics to China’s foremost farmers and pork producers.

 

The new production nucleus farm is expected to commence activities in October 2010 and when completed Genus will have established sufficient production capacity to enable its customers to breed an estimated 17 million pigs per year in China This represents almost twice the whole UK output for pigs.

For further information, please contact:

Genus plc

Tel: 01256 345970

Richard Wood, Chief Executive 

Martin Boden, Finance Director

Buchanan Communications

Tel: 020 7466 5000

Charles Ryland

Isabel Podda

Jennie Spivey

About Genus

Genus creates advances to animal breeding through biotechnology and sells added value products for livestock farming and food producers. Its non-genetically modified organism technology is applicable across all livestock species but is only commercialised by Genus in the bovine and porcine farming sectors.

Genus' worldwide sales are made in seventy countries under the trade marks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Customers' animals produce offspring with greater production efficiency, milk and meat output and quality and use these to supply the global dairy and meat supply chain.

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global production and distribution network.

Headquartered in BasingstokeEngland, Genus companies operate in 30 countries on six continents, with research laboratories located in MadisonWisconsinUSA.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCCKCKPOBKDQBD
Date   Source Headline
23rd Nov 20227:00 amRNSAGM Trading Update
3rd Nov 20227:00 amRNSRuthin Site Visit
14th Oct 202211:39 amRNSTR-1: Notification of Major Holdings
14th Oct 20227:00 amRNSAnnual Report and Annual General Meeting
15th Sep 202210:55 amRNSNotification of Major Holdings
14th Sep 20224:41 pmRNSDirector/PDMR Shareholding
13th Sep 20226:08 pmRNSDirector/PDMR Shareholding
8th Sep 20221:57 pmRNSNotification of Major Holdings
8th Sep 20227:00 amRNSPreliminary Results
2nd Sep 20229:05 amRNSTotal Voting Rights
2nd Aug 20227:00 amRNSAppointment of Joint Corporate Broker
1st Aug 202210:10 amRNSBlock listing Interim Review
21st Jul 202210:21 amBUSForm 8.3 - Genus Plc - CORRECTION
21st Jul 202210:05 amRNSHolding(s) in Company
20th Jul 20223:03 pmRNSNotification of Major Holdings
19th Jul 202211:57 amBUSForm 8.3 - Genus Plc
5th Jul 20222:10 pmRNSNotification of Major Holdings
1st Jul 20229:35 amRNSTotal Voting Rights
24th Jun 20223:42 pmRNSNotification of Major Holdings
6th Jun 20229:11 amRNSNotification of Major Holdings
1st Jun 202212:45 pmRNSNotification of Major Holdings
30th May 202212:18 pmRNSNotification of Major Holdings
17th May 20229:26 amRNSNotification of Major Holdings
21st Apr 20227:00 amRNSNotification of Major Holdings
19th Apr 20221:50 pmRNSNotification of Major Holdings
31st Mar 20221:34 pmRNSDirector Declaration
28th Mar 20225:36 pmRNSNotification of Major Holdings
8th Mar 20223:47 pmRNSNotification of Major Holdings
8th Mar 20221:13 pmRNSNotification of Major Holdings
24th Feb 20227:00 amRNSCollaboration between PIC and Olymel LP in Canada
24th Feb 20227:00 amRNSInterim Results
1st Feb 20224:57 pmRNSBlock listing Interim Review
4th Jan 20229:47 amRNSTotal Voting Rights
26th Nov 202110:18 amRNSDisclosure of Rights Attached to Equity Shares
24th Nov 20215:51 pmRNSDirector/PDMR Shareholding
24th Nov 20212:47 pmRNSResult of AGM
24th Nov 20212:30 pmRNSDirector/PDMR Shareholding
24th Nov 20217:00 amRNSAGM Trading Update
10th Nov 20212:28 pmRNSNotification of Major Holdings
15th Oct 20217:00 amRNSAnnual Report and Annual General Meeting
13th Oct 20215:56 pmRNSDirector/PDMR Shareholding
1st Oct 20213:58 pmRNSTotal Voting Rights
30th Sep 20219:59 amRNSDirector Declaration
29th Sep 20212:59 pmRNSNotification of Major Holdings
15th Sep 20214:45 pmRNSDirector/PDMR Shareholding
14th Sep 20214:32 pmRNSDirector/PDMR Shareholding
9th Sep 20217:00 amRNSPreliminary Results
1st Sep 20212:05 pmRNSTotal Voting Rights
2nd Aug 20214:00 pmRNSBlock listing Interim Review
2nd Aug 202110:09 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.